Clinical Significance of Ischemia-Modified Albumin in the Diagnosis of Doxorubicin-Induced Myocardial Injury in Breast Cancer Patients |
| |
Authors: | Yinghuan Ma Wanjun Kang Yongxin Bao Fubin Jiao Yiran Ma |
| |
Affiliation: | 1. Department of Cancer, The 463rd Hospital of the Chinese PLA, Shenyang, Liaoning, People’s Republic of China.; 2. Division of Health, Bureau of Guard, General Advisor Office of Chinese PLA, Beijing, People’s Republic of China.; 3. Department of Transfusion, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China.; Virginia Commonwealth University, United States of America, |
| |
Abstract: | BackgroundIschemia-modified albumin is an altered serum albumin that forms under conditions of oxidative stress, a state also associated with doxorubicin-induced myocardial injury.ObjectiveThe aim of this study was to better assess diagnostic and prognostic significance of ischemia-modified albumin in patients with breast cancer undergoing doxorubicin chemotherapy.MethodsBlood samples were collected from 152 breast cancer patients before and after each cycle of doxorubicin chemotherapy to measure the serum levels of ischemia-modified albumin, cardiac troponin T and creatine kinase-MB. We also monitored cardiac function during a 12 month follow-up.ResultsThere was a significant difference in ischemia-modified albumin levels before and after each cycle of chemotherapy and the ischemia-modified albumin concentration positively correlated with the cumulative dose of doxorubicin (r = 0.212, P < 0.05). The combination of ischemia-modified albumin with cardiac troponin T and creatine kinase-MB increased the sensitivity to 0.920 and the specificity to 0.830 in the diagnosis of doxorubicin-induced myocardial injury. The optimal cutoff for ischemia-modified albumin concentration was 112.09 U/ml. The rate of change for ischemia-modified albumin levels correlated negatively with the rate of change for left ventricular ejection fraction at one year (r = –0.221, P < 0.05).ConclusionIschemia-modified albumin may be a clinically potential new marker for diagnosing doxorubicin-induced myocardial injury, and is helpful to predict long-term impairment of cardiac function. |
| |
Keywords: | |
|
|